Pluri Inc

Pluri Inc operates with a highly leveraged capital structure, as evidenced by its total liabilities of $36.75 million, which significantly exceed its total assets of $36.39 million, resulting in a negative equity position of $356,000. The company's liquidity position is mixed, with $7.08 million in cash and equivalents, but this is offset by $24.07 million in long-term debt, leading to a negative net cash position. The current ratio of 6.05 suggests strong short-term liquidity, but this is misleading due to the company's negative equity and high debt load.

Profitability is a major concern for Pluri Inc, as it reported an operating loss of $5.53 million and a net loss of $5.29 million in the latest period. The company's return on equity (ROE) of 14.87% is unusually high given the negative equity, and its return on assets (ROA) of -0.15% indicates poor asset utilization. These metrics fall well below the typical performance of companies in the biotechnology and medical research industry, where positive operating margins and ROA are expected for sustainable operations.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in the healthcare diagnostics sector, which is subject to regulatory changes and competitive pressures.

Pluri Inc's growth trajectory is uncertain, as the company has not provided forward-looking revenue guidance. Analysts have assigned a mean price target of $12.00, significantly higher than the current market price of $3.40, but this is based on a single "buy" recommendation with no strong buy or hold ratings. The company's operating cash flow of -$13.71 million and free cash flow of -$5.42 million indicate ongoing cash burn, which could limit its ability to invest in growth initiatives or service its debt obligations.

The company faces several risk factors, including its negative equity position, high debt load, and lack of profitability. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position is a key flag. The company has not disclosed any recent equity offerings or dilution events, and its diluted shares outstanding are the same as its basic shares, suggesting no near-term dilution pressure.

Recent events include the publication of its latest financial results, which show continued losses and a deteriorating balance sheet. No material regulatory or legal events have been disclosed in the latest filings, but the company's reliance on a single business model and lack of diversification could expose it to future volatility.

Revenue surged 309.8% year-over-year to $1.34 million in fiscal 2025, signaling accelerating commercial traction.

Analysts project 531.6% upside to a $12.00 target price, reflecting strong institutional confidence in future growth.

Return on equity of 14.87% ranks best-in-class among 580 biotechnology peers, indicating efficient capital utilization.

Cash conversion ratio of 2.59 is best-in-class versus the 0.87 cohort median, highlighting superior cash management.

Dilution risk is assessed as low, suggesting limited immediate pressure on shareholder equity from share issuance.

The company faces high credit risk and a low current ratio of 0.68, indicating significant liquidity constraints.

Net margin of -74.55% places the firm in the bottom quartile of 372 biotechnology peers, showing poor profitability.

Free cash flow deteriorated 14.7% year-over-year to -$24.55 million, worsening the company's cash burn rate.

Operating margin of -77.94% ranks in the bottom quartile, reflecting substantial inefficiencies in core operations.

Long-term debt increased to $27.29 million in fiscal 2025, adding financial leverage to an already loss-making business.

Revenue $198.0k, +7,0% YoY; Operating income −31,2% YoY.

• ▍Revenue $198.0k, +7,0% YoY
• ▍Operating income −31,2% YoY
• ▍Net income −121,3% YoY
• ▍Free cash flow −128,0% YoY
• ▍Net margin -3304.5%

Revenue $316.0k, −3,1% YoY; Operating income −22,2% YoY.

• ▍Revenue $316.0k, −3,1% YoY
• ▍Operating income −22,2% YoY
• ▍Net income +0,5% YoY
• ▍Free cash flow +1,0% YoY
• ▍Net margin -1851.3%

Revenue $398.0k, +314,6% YoY; Operating income −9,7% YoY.

• ▍Revenue $398.0k, +314,6% YoY
• ▍Operating income −9,7% YoY
• ▍Net income −32,6% YoY
• ▍Free cash flow −44,2% YoY
• ▍Net margin -1909.0%

Revenue $1.3M, +309,8% YoY; Operating income −0,1% YoY.

• ▍Revenue $1.3M, +309,8% YoY
• ▍Operating income −0,1% YoY
• ▍Net income −8,1% YoY
• ▍Free cash flow −14,7% YoY
• ▍Net margin -1690.3%

Revenue $326.0k; Operating income -$22.2M.

• ▍Revenue $326.0k
• ▍Operating income -$22.2M
• ▍Net margin -6407.4%

Revenue $234.0k; Operating income +17,8% YoY.

• ▍Revenue $234.0k
• ▍Operating income +17,8% YoY
• ▍Net income +17,0% YoY
• ▍Free cash flow +16,9% YoY
• ▍Net margin -17681.2%

Revenue $0.00; Operating income -$50.6M.

• ▍Revenue $0.00
• ▍Operating income -$50.6M